New approaches to the management of schizophrenia: Focus on aberrant hippocampal drive of dopamine pathways

Stephanie M. Perez, Daniel J Lodge

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Schizophrenia is a disease affecting up to 1% of the population. Current therapies are based on the efficacy of chlorpromazine, discovered over 50 years ago. These drugs block dopamine D2-like receptors and are effective at primarily treating positive symptoms in a subset of patients. Unfortunately, current therapies are far from adequate, and novel treatments require a better understanding of disease pathophysiology. Here we review the dopamine, gamma-aminobutyric acid (GABA), and glutamate hypotheses of schizophrenia and describe a pathway whereby a loss of inhibitory signaling in ventral regions of the hippocampus actually drives a dopamine hyperfunction. Moreover, we discuss novel therapeutic approaches aimed at attenuating ventral hippocampal activity in a preclinical model of schizophrenia, namely the MAM GD17 rat. Specifically, pharmacological (allosteric modulators of the α5 GABAA receptor), neurosurgical (deep brain stimulation), and cell-based (GABAergic precursor transplants) therapies are discussed. By better understanding the underlying circuit level dysfunctions in schizophrenia, novel treatments can be advanced that may provide better efficacy and a superior side effect profile to conventional antipsychotic medications.

Original languageEnglish (US)
Pages (from-to)887-896
Number of pages10
JournalDrug Design, Development and Therapy
Volume8
DOIs
StatePublished - Jul 2 2014

Fingerprint

Dopamine
Schizophrenia
Therapeutics
Deep Brain Stimulation
Dopamine D2 Receptors
Chlorpromazine
GABA-A Receptors
gamma-Aminobutyric Acid
Antipsychotic Agents
Drive
Glutamic Acid
Hippocampus
Pharmacology
Transplants
Pharmaceutical Preparations
Population

Keywords

  • Dopamine
  • GABA
  • Glutamate
  • Hippocampus
  • MAM rat
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

New approaches to the management of schizophrenia : Focus on aberrant hippocampal drive of dopamine pathways. / Perez, Stephanie M.; Lodge, Daniel J.

In: Drug Design, Development and Therapy, Vol. 8, 02.07.2014, p. 887-896.

Research output: Contribution to journalArticle

@article{a44c551cab794404ba2f21e27c7435d1,
title = "New approaches to the management of schizophrenia: Focus on aberrant hippocampal drive of dopamine pathways",
abstract = "Schizophrenia is a disease affecting up to 1{\%} of the population. Current therapies are based on the efficacy of chlorpromazine, discovered over 50 years ago. These drugs block dopamine D2-like receptors and are effective at primarily treating positive symptoms in a subset of patients. Unfortunately, current therapies are far from adequate, and novel treatments require a better understanding of disease pathophysiology. Here we review the dopamine, gamma-aminobutyric acid (GABA), and glutamate hypotheses of schizophrenia and describe a pathway whereby a loss of inhibitory signaling in ventral regions of the hippocampus actually drives a dopamine hyperfunction. Moreover, we discuss novel therapeutic approaches aimed at attenuating ventral hippocampal activity in a preclinical model of schizophrenia, namely the MAM GD17 rat. Specifically, pharmacological (allosteric modulators of the α5 GABAA receptor), neurosurgical (deep brain stimulation), and cell-based (GABAergic precursor transplants) therapies are discussed. By better understanding the underlying circuit level dysfunctions in schizophrenia, novel treatments can be advanced that may provide better efficacy and a superior side effect profile to conventional antipsychotic medications.",
keywords = "Dopamine, GABA, Glutamate, Hippocampus, MAM rat, Schizophrenia",
author = "Perez, {Stephanie M.} and Lodge, {Daniel J}",
year = "2014",
month = "7",
day = "2",
doi = "10.2147/DDDT.S42708",
language = "English (US)",
volume = "8",
pages = "887--896",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - New approaches to the management of schizophrenia

T2 - Focus on aberrant hippocampal drive of dopamine pathways

AU - Perez, Stephanie M.

AU - Lodge, Daniel J

PY - 2014/7/2

Y1 - 2014/7/2

N2 - Schizophrenia is a disease affecting up to 1% of the population. Current therapies are based on the efficacy of chlorpromazine, discovered over 50 years ago. These drugs block dopamine D2-like receptors and are effective at primarily treating positive symptoms in a subset of patients. Unfortunately, current therapies are far from adequate, and novel treatments require a better understanding of disease pathophysiology. Here we review the dopamine, gamma-aminobutyric acid (GABA), and glutamate hypotheses of schizophrenia and describe a pathway whereby a loss of inhibitory signaling in ventral regions of the hippocampus actually drives a dopamine hyperfunction. Moreover, we discuss novel therapeutic approaches aimed at attenuating ventral hippocampal activity in a preclinical model of schizophrenia, namely the MAM GD17 rat. Specifically, pharmacological (allosteric modulators of the α5 GABAA receptor), neurosurgical (deep brain stimulation), and cell-based (GABAergic precursor transplants) therapies are discussed. By better understanding the underlying circuit level dysfunctions in schizophrenia, novel treatments can be advanced that may provide better efficacy and a superior side effect profile to conventional antipsychotic medications.

AB - Schizophrenia is a disease affecting up to 1% of the population. Current therapies are based on the efficacy of chlorpromazine, discovered over 50 years ago. These drugs block dopamine D2-like receptors and are effective at primarily treating positive symptoms in a subset of patients. Unfortunately, current therapies are far from adequate, and novel treatments require a better understanding of disease pathophysiology. Here we review the dopamine, gamma-aminobutyric acid (GABA), and glutamate hypotheses of schizophrenia and describe a pathway whereby a loss of inhibitory signaling in ventral regions of the hippocampus actually drives a dopamine hyperfunction. Moreover, we discuss novel therapeutic approaches aimed at attenuating ventral hippocampal activity in a preclinical model of schizophrenia, namely the MAM GD17 rat. Specifically, pharmacological (allosteric modulators of the α5 GABAA receptor), neurosurgical (deep brain stimulation), and cell-based (GABAergic precursor transplants) therapies are discussed. By better understanding the underlying circuit level dysfunctions in schizophrenia, novel treatments can be advanced that may provide better efficacy and a superior side effect profile to conventional antipsychotic medications.

KW - Dopamine

KW - GABA

KW - Glutamate

KW - Hippocampus

KW - MAM rat

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84903904315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903904315&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S42708

DO - 10.2147/DDDT.S42708

M3 - Article

C2 - 25061280

AN - SCOPUS:84903904315

VL - 8

SP - 887

EP - 896

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -